Sangamo Therapeutics (SGMO) Posts Earnings Results, Misses Expectations By $0.14 EPS

Share on StockTwits

Sangamo Therapeutics (NASDAQ:SGMO) announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.14), Morningstar.com reports. The business had revenue of $8.07 million for the quarter, compared to the consensus estimate of $27.21 million. Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%.

SGMO traded down $0.20 during midday trading on Friday, reaching $10.19. The company had a trading volume of 1,616,197 shares, compared to its average volume of 2,261,699. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -14.56 and a beta of 2.89. Sangamo Therapeutics has a 1 year low of $6.26 and a 1 year high of $19.25.

A number of research analysts have recently issued reports on SGMO shares. ValuEngine raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 26th. BidaskClub cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 25th. Wedbush set a $11.00 price objective on Sangamo Therapeutics and gave the company a “hold” rating in a research report on Tuesday. Finally, Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.00.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now owns 30,512 shares in the company, valued at $305,120. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders sold 20,000 shares of company stock valued at $210,550. Company insiders own 1.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Sangamo Therapeutics by 10.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,030 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 1,100 shares during the period. Principal Financial Group Inc. boosted its stake in Sangamo Therapeutics by 4.6% during the first quarter. Principal Financial Group Inc. now owns 29,405 shares of the biopharmaceutical company’s stock valued at $281,000 after buying an additional 1,303 shares during the last quarter. Macquarie Group Ltd. boosted its stake in Sangamo Therapeutics by 2.7% during the fourth quarter. Macquarie Group Ltd. now owns 53,852 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 1,400 shares during the last quarter. Legal & General Group Plc boosted its stake in Sangamo Therapeutics by 9.3% during the fourth quarter. Legal & General Group Plc now owns 18,066 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,534 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sangamo Therapeutics by 29.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,552 shares during the last quarter. 54.92% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics (SGMO) Posts Earnings Results, Misses Expectations By $0.14 EPS” was first posted by Tech Know Bits and is the sole property of of Tech Know Bits. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://techknowbits.com/2019/05/18/sangamo-therapeutics-sgmo-releases-earnings-results-misses-estimates-by-0-14-eps.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: How is inflation measured?

Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.